Anubhav Sahu Moneycontrol Research Highlights - Executive orders aimed at reducing drug prices by squeezing middlemen - To cap drug prices based on prices in economically comparable countries - Orders likely to have a lesser impact on generic players - Any positive outcome on market access front can benefit Indian pharma - Companies to watch: Cipla, Cadila, Lupin, Dr Reddy’s, Sun Pharma, Laurus and Biocon President Donald Trump’s executive orders, aimed at substantially reducing drug prices for the US residents, underscore the campaign pitch of the next election. Pharma pricing has...
Moneycontrol Pro Panorama | GST: A simple, reliable tax still a distant dream?
May 20, 2022 / 04:41 PM IST
In today’s edition of Moneycontrol Pro Panorama: A peek into Strategy Lab, ITC makes it to Weekly Tactical, wide canvas for Nazara, shock proof your portfolio and moreRead Now
Moneycontrol Pro Weekender | People’s Bank of China rides to the rescue
May 21, 2022 / 10:10 AM IST
The central bank of China – an outlier in these times of quantitative tightening – has eased its policy to salvage the Chinese economy. And the messaging is not lost on global growthRead Now
To read the full story, Subscribe to Moneycontrol PRO
Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience
Already a member? Sign in
Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to
Ad free experience
Experience a non-intrusive navigation and faster response in the ad free mode
Access to 230+ exclusive stories per month from our editorial and Experts
Have a Global edge with access to content from world renowned experts and journalist
Access to 40+ weekly investment ideas including 4 daily technical calls
Exclusive access to live webinars from market experts on trading and investment strategies
Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.
Get upto 50% discount on limited period offers